Leerink Partners analyst Andrew Berens lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $880.00 (from $1,077.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE